These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23115650)

  • 21. Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi.
    Niyibitegeka F; Riewpaiboon A; Youngkong S; Thavorncharoensap M
    Vaccine; 2021 Feb; 39(8):1272-1282. PubMed ID: 33487467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
    Abbott C; Tiede B; Armah G; Mahmoud A
    Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost-effectiveness of rotavirus vaccination in Australia.
    Newall AT; Beutels P; Macartney K; Wood J; MacIntyre CR
    Vaccine; 2007 Dec; 25(52):8851-60. PubMed ID: 18022735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
    Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
    Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of childhood rotavirus vaccination in Germany.
    Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
    Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic impact of a rotavirus vaccination program in Mexico.
    Constenla D; Velázquez FR; Rheingans RD; Antil L; Cervantes Y
    Rev Panam Salud Publica; 2009 Jun; 25(6):481-90. PubMed ID: 19695142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.
    Standaert B; Parez N; Tehard B; Colin X; Detournay B
    Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium.
    Bilcke J; Van Damme P; Beutels P
    Med Decis Making; 2009; 29(1):33-50. PubMed ID: 18948433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of a rotavirus immunization program for the United States.
    Tucker AW; Haddix AC; Bresee JS; Holman RC; Parashar UD; Glass RI
    JAMA; 1998 May; 279(17):1371-6. PubMed ID: 9582045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
    Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
    Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
    PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A benefit-risk analysis of rotavirus vaccination, France, 2015.
    Lamrani A; Tubert-Bitter P; Hill C; Escolano S
    Euro Surveill; 2017 Dec; 22(50):. PubMed ID: 29258644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of rotavirus vaccination in Armenia.
    Jit M; Yuzbashyan R; Sahakyan G; Avagyan T; Mosina L
    Vaccine; 2011 Nov; 29(48):9104-11. PubMed ID: 21945959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
    Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
    BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world effectiveness of rotavirus vaccines, 2006-19: a literature review and meta-analysis.
    Burnett E; Parashar UD; Tate JE
    Lancet Glob Health; 2020 Sep; 8(9):e1195-e1202. PubMed ID: 32827481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the introduction of universal rotavirus vaccination in the Netherlands.
    Zomer TP; van Duynhoven YT; Mangen MJ; van der Maas NA; Vennema H; Boot H; de Melker HE
    Vaccine; 2008 Jul; 26(29-30):3757-64. PubMed ID: 18514975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq.
    Weycker D; Sofrygin O; Kemner JE; Pelton SI; Oster G
    Vaccine; 2009 Aug; 27(36):4930-7. PubMed ID: 19555715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis.
    Rose J; Homa L; Meropol SB; Debanne SM; Bielefeld R; Hoyen C; Singer ME
    PLoS One; 2017; 12(11):e0187446. PubMed ID: 29099848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.